1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid has been researched along with rosiglitazone in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azukizawa, S; Fukui, M; Kamemoto, H; Kasai, M; Kunishiro, K; Miike, T; Otake, K; Shibabayashi, M; Shirahase, H | 1 |
1 other study(ies) available for 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid and rosiglitazone
| Article | Year |
|---|---|
A novel series of (S)-2,7-substituted-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids: peroxisome proliferator-activated receptor α/γ dual agonists with protein-tyrosine phosphatase 1B inhibitory activity.
Topics: Animals; Blood Glucose; Carboxylic Acids; Cricetinae; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation, Preclinical; Enzyme Inhibitors; Humans; Hypoglycemic Agents; Male; Mice; Mice, Inbred ICR; Molecular Targeted Therapy; Peroxisome Proliferator-Activated Receptors; Protein Tyrosine Phosphatases; Quinazolinones; Rosiglitazone; Tetrahydroisoquinolines; Thiazolidinediones | 2011 |